Comments
Dr Reddy’s Laboratories has announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9 Sodium Chloride Injection, approved by the US Food and Drug Administration (USFDA).
“We are pleased to bring this important generic product to market, making it affordable — and readily available — for patients,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddy’s Laboratories. “Our ability to adequately supply Dexmedetomidine is important for patients as it is on the FDA’s Drug Shortage list.”
Also read: Dr Reddy’s trials for Russia’s Sputnik-V vaccine could start in next few weeks
The Precedex in 0.9% Sodium Chloride Injection brand and generic market had US sales of approximately $210 million MAT for the most recent 12 months ended in June 2020, according to IQVIA Health.
Dr Reddy’s Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 200 mcg/50 mL (4 mcg/mL) and 400 mcg/100 mL (4 mcg/mL) in 50 mL and 100 mL clear glass vials, respectively. The strength is based on the dexmedetomidine base. Containers are intended for single-dose only.
Precedex is a trademark owned or licensed by of Hospira, Inc.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.